Identification of circulating plasma ceramides as a potential sexually dimorphic biomarker of pancreatic cancer‐induced cachexia
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: Cancer patients who exhibit cachexia lose weight and have low treatment tolerance and poor outcomes compared to cancer patients without weight loss. Despite the clear increased risk for patients, diagnosing cachexia still often relies on self-reported weight loss. A reliable biomarker to identify patients with cancer cachexia would be a valuable tool to improve clinical decision making and identification of patients at risk of adverse outcomes. Methods: Targeted metabolomics, that included panels of amino acids, tricarboxylic acids, fatty acids, acylcarnitines, and sphingolipids, were conducted on plasma samples from patients with confirmed pancreatic ductal adenocarcinoma (PDAC) with and without cachexia and control patients without cancer (n=10/group, equally divided by sex). Additional patient samples were analyzed (total n=95) and Receiver Operating Characteristic (ROC) analyses were performed to establish if any metabolite could effectively serve as a biomarker of cachexia. Results: Targeted profiling revealed that cachectic patients had decreased circulating levels of three sphingolipids compared to either non-cachectic PDAC patients or patients without cancer. The ratio of C18-ceramide to C24-ceramide (C18:C24) outperformed a number of other previously proposed biomarkers of cachexia (area under ROC = 0.810). It was notable that some biomarkers, including C18:C24, were only altered in cachectic males. Conclusions: Our findings identify C18:C24 as a potentially new biomarker of PDAC-induced cachexia that also highlight a previously unappreciated sexual dimorphism in cancer cachexia.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Identification of circulating plasma ceramides as a potential sexually dimorphic biomarker of pancreatic cancer‐induced cachexia
- Date Crossref
- 20/06/2022
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Arthur G. James Comprehensive Cancer Center Cancer Cachexia Program pays non établi dans la noticeÉtablissement de santé
-
Kaiser Permanente Walnut Creek Medical Center Department of General Surgery pays non établi dans la noticeÉtablissement de santé
-
The Ohio State University Critical Care pays non établi dans la noticeUniversité ou école supérieure
-
West Virginia University Department of Surgery pays non établi dans la noticeUniversité ou école supérieure
-
OhioHealth pays non établi dans la noticeÉtablissement de santé
-
City Of Hope National Medical Center Department of Radiation Oncology pays non établi dans la noticeÉtablissement de santé
-
Medical University of South Carolina Department of Pediatrics pays non établi dans la noticeUniversité ou école supérieure
-
MUSC Hollings Cancer Center pays non établi dans la noticeÉtablissement de santé
-
University of Iowa Department of Health and Human Physiology and Holden Comprehensive Cancer Center pays non établi dans la noticeUniversité ou école supérieure
Arthur G. James Comprehensive Cancer Center Cancer Cachexia Program — The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Department of General Surgery — Kaiser Permanente Walnut Creek Medical Center et Critical Care — The Ohio State University, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.